LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Peter R. Gebauer sold 6,224 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.85, for a total value of $210,682.40. Following the completion of the transaction, the insider now owns 8,477 shares in the company, valued at approximately $286,946.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of LeMaitre Vascular, Inc. (LMAT) traded down 1.47% during mid-day trading on Wednesday, reaching $33.56. The company’s stock had a trading volume of 143,476 shares. LeMaitre Vascular, Inc. has a 12 month low of $16.80 and a 12 month high of $36.09. The company has a 50 day moving average price of $29.79 and a 200 day moving average price of $26.87. The stock has a market capitalization of $631.43 million, a P/E ratio of 47.94 and a beta of 0.65.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The business had revenue of $25.80 million during the quarter, compared to analysts’ expectations of $25.42 million. During the same quarter last year, the company earned $0.14 earnings per share. The firm’s revenue was up 15.2% on a year-over-year basis. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular announced that its board has authorized a stock buyback plan on Thursday, July 27th that authorizes the company to repurchase $7.50 million in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd will be paid a $0.055 dividend. This represents a $0.22 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Monday, August 21st. LeMaitre Vascular’s payout ratio is presently 31.88%.

ILLEGAL ACTIVITY NOTICE: “Peter R. Gebauer Sells 6,224 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock” was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/09/peter-r-gebauer-sells-6224-shares-of-lemaitre-vascular-inc-nasdaqlmat-stock.html.

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA boosted its stake in LeMaitre Vascular by 11,612.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 3,716 shares during the last quarter. Royce & Associates LP bought a new stake in LeMaitre Vascular during the second quarter valued at $156,000. Oppenheimer Asset Management Inc. boosted its stake in LeMaitre Vascular by 4,751.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,355 shares of the medical instruments supplier’s stock valued at $198,000 after buying an additional 6,224 shares during the last quarter. American International Group Inc. boosted its stake in LeMaitre Vascular by 7.0% in the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 545 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in LeMaitre Vascular during the second quarter valued at $206,000. Institutional investors and hedge funds own 67.10% of the company’s stock.

LMAT has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price target on shares of LeMaitre Vascular in a research note on Thursday, April 27th. Stifel Nicolaus boosted their price target on LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Benchmark Co. cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Monday, July 10th. They noted that the move was a valuation call. Craig Hallum initiated coverage on LeMaitre Vascular in a research note on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price target on the stock. Finally, Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Buy” and an average target price of $30.17.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.